



(51) International Patent Classification:

C07K 14/81 (2006.01) C12N 15/86 (2006.01)

A61P 7/10 (2006.01)

(21) International Application Number:

PCT/US2020/060337

(22) International Filing Date:

13 November 2020 (13.11.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/935,359 14 November 2019 (14.11.2019) US

63/016,365 28 April 2020 (28.04.2020) US

(71) Applicant: BIOMARIN PHARMACEUTICAL INC.

[US/US]; 105 Digital Drive, Novato, CA 94949 (US).

(72) Inventor: COLOSI, Peter; 105 Digital Drive, Novato, CA

94949 (US).

(74) Agent: DOLA, Kristen, A. et al.; Rinlaures LLC, 321 N.

Clark St., 5th Floor, Chicago, IL 60654 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TREATMENT OF HEREDITARY ANGIOEDEMA WITH LIVER-SPECIFIC GENE THERAPY VECTORS

(57) Abstract: Provided herein are compositions and methods for treating a C1 esterase inhibitor deficiency by normalizing levels of the C1 esterase inhibitor protein in a subject having HAE.



WO 2021/097157 A1